source
- Lilly, Gilead lead pharma’s M&A boomDeal volume in 2026 is substantially outpacing last year, and activity is being driven by interest in cancer and autoimmune disease drugs.
- FDA proposes stripping gender references from regulations, prompting research concernsThe U.S. Food and Drug Administration has issued a proposal to eliminate references to gender in its regulatory language. The change is intended to modernize the rules but has drawn attention from…